HCW Biologics Inc. Price & Performance (HCWB)

HCW Biologics stock fell sharply today, dropping more than 13% to $6.90, continuing a steep annual decline that now totals nearly 89%. The company’s market value has been battered by persistent losses, high debt, and liquidity concerns, raising questions about its ability to rebound without significant new funding.12

Facing delisting threats, HCW Biologics will enact a 1-for-40 reverse stock split effective April 11. The move slashes outstanding shares from nearly 45 million to just over 1.1 million, aiming to boost the share price above Nasdaq’s $1 minimum. Shareholder ownership percentages remain unchanged, but liquidity may be impacted.345

HCW Biologics has received FDA clearance to initiate a Phase 1 trial for HCW9302, targeting moderate-to-severe alopecia areata. This marks the company’s first foray into quality-of-life indications, expanding beyond its cancer and age-related disease pipeline, and could provide new momentum amid ongoing financial challenges.67